Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)

被引：23

作者：

Zhu, Andrew X. ^{[1
,2
]}

Guan, Yinghui ^{[3
]}

Abbas, Alexander R. ^{[3
]}

Koeppen, Hartmut ^{[3
]}

Lu, Shan ^{[3
]}

Hsu, Chih-Hung ^{[4
]}

Lee, Kyung-Hun ^{[5
]}

Lee, Michael S. ^{[6
]}

He, Aiwu Ruth ^{[7
]}

Mahipal, Amit ^{[8
]}

Ding, Beiying ^{[3
]}

Spahn, Jessica ^{[3
]}

Verret, Wendy ^{[3
]}

Ryoo, Baek-Yeol ^{[9
]}

Wang, Yulei ^{[3
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[2] Jiahui Int Canc Ctr, Boston, MA USA

[3] Genentech Inc, San Francisco, CA 94080 USA

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] Seoul Natl Univ, Seoul, South Korea

[6] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[7] Georgetown Univ, Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[8] Mayo Clin, Rochester, MN USA

[9] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-CT044

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT044

引用

页数：2

共 50 条

[21] Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
Han, Ji Won
Jang, Jeong Won
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
[22] Therapy with Atezolizumab and Bevacizumab prolongs Life of Patients with hepatocellular Carcinoma
Kessing, Richard
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (09):
[23] Updated safety and clinical activity results from a phase Ib study of atezolizumab 1 bevacizumab in hepatocellular carcinoma (HCC)
Pishvaian, M. J.
Lee, M. S.
Ryoo, B-Y.
Stein, S.
Lee, K-H.
Verret, W.
Spahn, J.
Shao, H.
Liu, B.
Iizuka, K.
Hsu, C-H.
ANNALS OF ONCOLOGY, 2018, 29
[24] Real-world systemic treatment patterns of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC)
Singal, A. G.
Ozgurdal, K.
Fan, X.
Vassilev, Z.
Chen, C-C.
Multani, J. K.
Zhou, Z.
He, J.
Pisa, F.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S867 - S867
[25] Bevacizumab combined with atezolizumab or sintilimab as second-line treatment in patients with advanced hepatocellular carcinoma: A retrospective study.
Gan, Leijuan
Li, Huikai
Wu, Qiang
Li, Qiang
Cui, Yunlong
Zhang, Wei
Fang, Feng
Lu, Wei
Li, Guangtao
Ren, Shaohua
Liu, Yayue
Lang, Mengran
Han, Ruyu
Song, Tianqiang
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 544 - 544
[26] Management of patients with advanced HCC receiving atezolizumab/bevacizumab: Take care of cirrhosis!
Nault, Jean-Charles
Iavarone, Massimo
HEPATOLOGY, 2024,
[27] Tumor microenvironment and clinical efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma
Taira, Tomonao
Kojima, Motohiro
Yamaguchi, Shota
Inoue, Kanae
Eguchi, Hiroki
Okumura, Kei
Shibuki, Taro
Satake, Tomoyuki
Watanabe, Kazuo
Sasaki, Mitsuhito
Imaoka, Hiroshi
Mitsunaga, Shuichi
Ishii, Genichiro
Ikeda, Masafumi
ANNALS OF ONCOLOGY, 2023, 34 : S1399 - S1399
[28] Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
Xin, Yujing
Cao, Fei
Yang, Hongcai
Zhang, Xinyuan
Chen, Yi
Cao, Xiaojing
Zhou, Xiang
Li, Xiao
Zhou, Jinxue
FRONTIERS IN IMMUNOLOGY, 2022, 13
[29] Atezolizumab and bevacizumab for advanced hepatocellular carcinoma: a single centre real world experience
Tan, Pei Ying
Hui, Samuel
O'Neill, Paul
Dev, Anouk
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 142 - 143
[30] Atezolizumab and bevacizumab in advanced hepatocellular carcinoma: Real-world data.
Bezalel, Nomi
Davidov, Yana
Likhter, Mariya
Ezra, Oranit Cohen
Inbar, Yael
Halpern, Naama
Ben Boursi
Beller, Tamar
Pery, Ron
Shmueli, Einat S.
Nachmany, Ido
Ben Ari, Ziv
Margalit, Ofer
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →